Article
Management of patients with multi-drug resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
Registro en:
LANGE, Christoph et al. Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J , v.44, n.1, p.23–63, 2014.
1399-3003
10.1183/09031936.00188313
Autor
Lange, Christoph
Abubakar, Ibrahim
Alffenaar, Jan-Willem C
Bothamley, Graham
Caminero, Jose A
Carvalho, Anna Cristina Calçada
Chang, Kwok-Chiu
Codecasa, Luigi
Correia, Ana
Crudu, Valeriu
Davies, Peter
Dedicoat, Martin
Drobniewski, Francis
Duarte, Raquel
Ehlers, Cordula
Erkens, Connie
Goletti, Delia
Günther, Gunar
Ibraim, Elmira
Kampmann, Beate
Kuksa, Liga
Lange, Wiel de
van Leth, Frank
van Lunzen, Jan
Matteelli, Alberto
Menzies, Dick
Monedero, Ignacio
Richter, Elvira
Rüsch-Gerdes, Sabine
Sandgren, Andreas
Scardigli, Anna
Skrahina, Alena
Tortoli, Enrico
Volchenkov, Grigory
Wagner, Dirk
van der Werf, Marieke J
Williams, Bhanu
Yew, Wing-Wai
Zellweger, Jean-Pierre
Cirillo, Daniela Maria
Resumen
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR)
tuberculosis (TB) substantially challenges TB control, especially in the European Region of the World
Health Organization, where the highest prevalence of MDR/XDR cases is reported. The current
management of patients with MDR/XDR-TB is extremely complex for medical, social and public health
systems. The treatment with currently available anti-TB therapies to achieve relapse-free cure is long and
undermined by a high frequency of adverse drug events, suboptimal treatment adherence, high costs and
low treatment success rates. Availability of optimal management for patients with MDR/XDR-TB is limited
even in the European Region. In the absence of a preventive vaccine, more effective diagnostic tools and
novel therapeutic interventions the control of MDR/XDR-TB will be extremely difficult. Despite recent
scientific advances in MDR/XDR-TB care, decisions for the management of patients with MDR/XDR-TB
and their contacts often rely on expert opinions, rather than on clinical evidence.
This document summarises the current knowledge on the prevention, diagnosis and treatment of adults
and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on
questions where scientific evidence is still lacking.